内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

PUDF 2013：母义明-GLP-1受体激动剂，它们都一样吗？

2013-05-30 佚名 糖化教育网

PUDFGLP-1受体激动剂降糖药体重胰岛素胰高糖素
关注

 　　2013年5月3日至5日，第九届“北大糖尿病论坛”如期在北京成功举办。围绕“肥胖与糖尿病新解”的主题，在2013年5月5日下午“体重与基于GLP-1的治疗”专场中，来自中国人民解放军总医院的母义明教授对各种GLP-1受体激动剂进行了比较。母义明教授的报告题目是“GLP-1受体激动剂，它们都一样吗？”。 图1 母义明教授 　　母义明教授指出，GLP-1受体激动剂是一种重要的新型降

 　　2013年5月3日至5日，第九届“北大糖尿病论坛”如期在北京成功举办。围绕“肥胖与糖尿病新解”的主题，在2013年5月5日下午“体重与基于GLP-1的治疗”专场中，来自中国人民解放军总医院的母义明教授对各种GLP-1受体激动剂进行了比较。母义明教授的报告题目是“GLP-1受体激动剂，它们都一样吗？”。

图1 母义明教授

　　母义明教授指出，GLP-1受体激动剂是一种重要的新型降糖药，可部分纠正2型糖尿病的GLP-1缺乏 ，以葡萄糖依赖的方式增加胰岛β细胞的胰岛素分泌，减少胰岛α细胞的胰高血糖素分泌，延迟胃排空，减少食物摄入，增加饱腹感。
　　母义明教授指出，GLP-1受体激动剂可以根据结构分为基于GLP-1和基于Exendin-4治疗两类；根据药代动力学可分为短效和长效；根据对胃排空的影响及主要是降低FPG还是PPG分为餐时和非餐时，但餐时及非餐时属于暂时性的命名。


 
　　餐时GLP-1 作用于餐后血糖的主要决定因素包括刺激胰岛素分泌、抑制胰高糖素分泌和延迟胃排空，其中，胃排空率是2型糖尿病患者餐后血糖的一个重要决定因素。非餐时GLP-1 受体激动剂对血糖作用主要作用于胰腺的胰岛素及胰高糖素分泌，而不是胃排空。
　　对各种GLP-1受体激动剂的比较发现，利拉鲁肽降低体重的作用是最强的，而在低血糖、副作用和对血压及心率的影响方面，各种GLP-1 受体激动剂有所不同，但其机制及临床意义还需进一步证实。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792907, encodeId=f2721e929074c, content=<a href='/topic/show?id=3625148e955' target=_blank style='color:#2F92EE;'>#PUDF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14879, encryptionId=3625148e955, topicName=PUDF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Jan 27 12:05:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294018, encodeId=cc921294018bd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422677, encodeId=4c5414226e7c3, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627717, encodeId=29d0162e71711, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=)]
    2014-01-27 AspirantSuo

    #PUDF#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1792907, encodeId=f2721e929074c, content=<a href='/topic/show?id=3625148e955' target=_blank style='color:#2F92EE;'>#PUDF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14879, encryptionId=3625148e955, topicName=PUDF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Jan 27 12:05:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294018, encodeId=cc921294018bd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422677, encodeId=4c5414226e7c3, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627717, encodeId=29d0162e71711, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=)]
    2013-06-01 Eleven11

    #GLP-1受体激动剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1792907, encodeId=f2721e929074c, content=<a href='/topic/show?id=3625148e955' target=_blank style='color:#2F92EE;'>#PUDF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14879, encryptionId=3625148e955, topicName=PUDF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Jan 27 12:05:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294018, encodeId=cc921294018bd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422677, encodeId=4c5414226e7c3, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627717, encodeId=29d0162e71711, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=)]
    2013-06-01 yibei

    #GLP-1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1792907, encodeId=f2721e929074c, content=<a href='/topic/show?id=3625148e955' target=_blank style='color:#2F92EE;'>#PUDF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14879, encryptionId=3625148e955, topicName=PUDF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Mon Jan 27 12:05:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294018, encodeId=cc921294018bd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422677, encodeId=4c5414226e7c3, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627717, encodeId=29d0162e71711, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 01 02:05:00 CST 2013, time=2013-06-01, status=1, ipAttribution=)]
    2013-06-01 medscijoin

    #激动剂#

    0